266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
| Autor: | Piccart, M., Ruiz Borrego, M., Arkenau, H-T., Escrivá-de-Romaní, S.I., Howell, S.J., Hennequin, A., Jimenez-Rodriguez, B., Del Conte, G., Simonelli, M., Palleschi, M., Duhoux, F., Doger De Speville Uribe, B., Curigliano, G., Waters, S., Aftimos, P.G., Wildiers, H., Tosi, D., Amair-Pinedo, F., Pellacani, A.U.E., Laurent, D.O. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S478-S479 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|